Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SCHERING-PLOUGH

(SGP)
SummaryNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SCHERING-PLOUGH : Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males

05/19/2009 | 07:37am EST

Specially designed microsite (www.meettheburns.com) targets first time athlete's foot sufferers and parents.

KENILWORTH, N.J., May 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced the arrival of TINACTIN(R) CHILL, an antifungal spray for the treatment of athlete's foot. TINACTIN CHILL is available in two formulations, liquid spray and deodorant powder spray.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090519/NY19030 )

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/tinactin/38431/

Athlete's foot is an infection caused by direct contact with fungus. People are most susceptible when their feet are sweating or when wearing shoes that lack proper ventilation. The condition is commonly picked up by walking barefoot in locker rooms, pools and other public areas.

TINACTIN CHILL is targeted to address the needs of the first time athlete's foot sufferer, which are primarily young males ages 14 to 22. "Research shows that experiencing athlete's foot for the first time can be very frightening and intimidating for young men," said John O'Mullane, PhD., group vice president, research and development, Schering-Plough Consumer Healthcare. "Our research indicated that to reach this age group we would need to go beyond the traditional methods of communication with our customers."

To reach this audience, Schering-Plough developed an innovative Web site, www.meettheburns.com. The site features a series of "Webisodes" highlighting the fictitious Burns family and a character named "Gus" representing fungus. Each segment presents an athlete's foot treatment message in a situation comedy style that is entertaining and identifies well with teens. "Many young men are reluctant to talk about their situation when they first experience athlete's foot," O'Mullane said. "However, they often seek information on the Internet. By developing this Web site, we can reach young men and help inform them and their parents that there are effective and easy to use treatments for this common condition."

About TINACTIN CHILL

TINACTIN CHILL is clinically proven to cure most athlete's foot and can even help prevent athlete's foot with daily use. The Liquid Spray contains ingredients that provide an extra cooling sensation and the Deodorant Powder Spray will fight odor all day long in addition to treating athlete's foot.

TINACTIN CHILL is available at most mass retailers, drugstores, grocery stores and online outlets.

About Schering-Plough

Schering-Plough Consumer Health Care is the U.S. over-the-counter (OTC) and consumer products business unit of Schering-Plough, an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SOURCE Schering-Plough Corporation


ę PRNewswire 2009
All news about SCHERING-PLOUGH
2009SCHERING-PLOUGH : Announces Sponsorship of Rabies-Control Projects in India
PR
2009SCHERING-PLOUGH : Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary En..
PR
2009SCHERING-PLOUGH : U.S. Food and Drug Administration Issues Complete Response Letter Regard..
PR
2009SCHERING-PLOUGH : Standard & Poor's Announces Changes to U.S. Indices
PR
2009SCHERING-PLOUGH : Reports Financial Results for 2009 Third Quarter
PR
2009SCHERING-PLOUGH : Nobilon Advances Intranasal Seasonal Influenza Vaccine Into Proof of Con..
PR
2009SCHERING-PLOUGH : Schedules Conference Call Webcast For 2009 Third Quarter Earnings
PR
2009SCHERING-PLOUGH : SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcu..
PR
2009SCHERING-PLOUGH : Declares Quarterly Dividends on Common Shares and Mandatory Convertible ..
PR
2009SCHERING-PLOUGH : Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Stu..
PR
More news